|
OCGN | Ocugen, Inc. |
|
|
OCGN | Ocugen, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.01 |
| Leverage | 93.87% |
| Market Cap | $ 407.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -63.8m |
| Margin | -1521.49% |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.